What does NewLimit do?
NewLimit is a South San Francisco-based developer of medicines that add healthy years to human life by leveraging the emerging science of epigenetic reprogramming to target aging, a key driver behind many major diseases.
How much did they raise?
The company raised $130M in a Series B funding round, with Kleiner Perkins as the lead investor and participation from Nat Friedman, Daniel Gross, Khosla Ventures, Human Capital, Valor Equity Partners, and several existing investors including Dimension and Founders Fund.
What are their plans for the money?
NewLimit intends to use the funds to expand its operations and accelerate its research and development efforts, potentially transforming the way aging is addressed in medicine and paving the way for therapies that could drastically extend healthy human lifespans.
What have they achieved so far?
The company has made significant early strides by harnessing the potential of epigenetic reprogramming—a breakthrough that challenges the long-held belief that aging is irreversible—establishing itself at the forefront of a transformative movement in biotech.
